Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
Sign Up to like & getrecommendations! Published in 2021 at "Cell chemical biology"
DOI: 10.1016/j.chembiol.2021.08.012
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-density lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDLR) degradation. Therapeutic antibodies that disrupt PCSK9-LDLR binding reduce LDL-C concentrations and cardiovascular disease risk. The epidermal… read more here.
Keywords: ldlr disruptor; pcsk9; pcsk9 ldlr; function ... See more keywords
In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of bioscience and bioengineering"
DOI: 10.1016/j.jbiosc.2020.10.009
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) induces low-density lipoprotein (LDL)-receptor (LDLR) degradation, increasing plasma LDL-cholesterol levels and causing hypercholesterolemia. Therefore, inhibition of PCSK9-LDLR interaction is an attractive therapeutic target for hypercholesterolemia treatment. In this study,… read more here.
Keywords: rna aptamer; ldl uptake; ldlr interaction; pcsk9 ldlr ... See more keywords
Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 Are Associated with Serum Lipid Profile in Chinese Han Population
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Environmental Research and Public Health"
DOI: 10.3390/ijerph16173207
Abstract: Unfavorable serum lipid levels are the most important risk factors for coronary artery disease (CAD), cerebral infarction, and other cardiovascular and cerebrovascular diseases. This study included 2323 Han Chinese in southern China. We collected medical… read more here.
Keywords: risk; snps; slc12a3; polymorphisms pcsk9 ... See more keywords